GC
ECYT

Guggenheim Capital’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Guggenheim Capital’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-15,972
Closed -$145K – 2756
2018
Q1 		$145K Buy
+15,972
New +$88.1K ﹤0.01% 2640
2017
Q4 		– Sell
-10,433
Closed -$15K – 2886
2017
Q3 		$15K Sell
10,433
-29
-0.3% -$40 ﹤0.01% 2764
2017
Q2 		$16K Sell
10,462
-1,266
-11% -$2.72K ﹤0.01% 2798
2017
Q1 		$30K Buy
+11,728
New +$27.1K ﹤0.01% 2757
2014
Q4 		– Sell
-216,734
Closed -$1.32M – 3154
2014
Q3 		$1.32M Buy
216,734
+6,129
+3% +$41.9K ﹤0.01% 2052
2014
Q2 		$1.39M Buy
+210,605
New +$2.37M ﹤0.01% 2073

Other funds holding ECYT

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Guggenheim Capital's ECYT Position: Q2 2018 in Review

Guggenheim Capital sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 15,972 shares — an estimated $145K sold.

Guggenheim Capital first reported a position in ECYT in Q2 2014 and held it in 6 quarters. The position peaked at $1.39M in Q2 2014. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.

  • Guggenheim Capital reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 15,972 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $145K.
  • Guggenheim Capital first reported a position in Endocyte, Inc. Common Stock in Q2 2014 and held it in 6 quarters.
  • Guggenheim Capital's Endocyte, Inc. Common Stock position peaked at $1.39M in Q2 2014.
  • 114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.